Release date: 2015-06-04
The US government health agency announced on the 1st that a "groundbreaking" clinical trial of precision medicine will be launched in July this year, which will bring new hopes for the use of targeted therapy to cancer patients with specific genetic abnormalities.
The trial, called NCI-MATCH, will include more than 20 drugs or combinations of drugs, each targeting a specific genetic mutation, some of which have been approved for marketing, and others are still in trial. The start-up phase of the trial was divided into two steps. The first was to perform genome sequencing on 3,000 cancer patients to clarify the genetic mutations that drive tumor growth. Second, 1,000 subjects were selected from these patients, and their genetic mutations were available. Or combination therapy, then assign them to different research groups, up to 35 people per group.
The National Cancer Institute acting director, Loy, said in a statement that NCI-MATCH is a "unique, groundbreaking experiment" that "has the potential to revolutionize cancer treatment."
According to the study, patients who meet the test conditions must be those with solid tumors or lymphoma who are 18 years of age or older who do not respond to at least one standard treatment. According to the design requirements, at least one-quarter of these people are rare cancer patients, such as cancer with eyes, ureters, pituitary gland and other parts.
There are two goals in the trial. One is to see if there is a response to the drug, that is, whether the tumor has a reduction in thickness, width or length by at least 30%. If 16% to 25% of the patients in the study group respond to the drug, the drug is considered promising; if less than 5% of the patients respond, the drug will be considered a failure. The second is to observe whether the drug will keep the disease stable for at least 6 months. If less than 15% of the patients meet this requirement, the drug will be regarded as a failure; if more than 35% of the patients meet this requirement, the drug will be treated as For further evaluation.
At present, most drugs are designed for “general patientsâ€, and the medications are “one size fits allâ€. As a result, it is effective for some patients and not for others. To change this situation, the US government launched the "Precision Medicine Program" in January this year, with the goal of matching specific therapies according to the patient's genes. US President Barack Obama believes that precision medicine will "lead a new era of medicine."
Source: Xinhuanet
Briquette Machine,Biomass Briquette Machines,Sawdust Briquette Machinery,Small Briquette Machine
Shandong Longze Mechanical Equipment Co.,Ltd , https://www.pelletmachinefactory.com